{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:59:01Z","timestamp":1789754341037,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ygyno.2010.10.003","type":"journal-article","created":{"date-parts":[[2010,10,30]],"date-time":"2010-10-30T08:33:22Z","timestamp":1288427602000},"page":"121-127","source":"Crossref","is-referenced-by-count":73,"title":["A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3\u2032-kinase (PI3K)\/AKT pathway in ovarian cancer cells"],"prefix":"10.1016","volume":"120","author":[{"given":"Seung Bae","family":"Rho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boh-Ram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokbom","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2010.10.003_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","article-title":"Maximal cytoreductive effort in epithelial ovarian cancer surgery","volume":"21","author":"Shih","year":"2010","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0015","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/sj.onc.1207115","article-title":"PI3K\/Akt and apoptosis: size matters","volume":"22","author":"Franke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0020","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway","volume":"96","author":"Cantley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0025","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1158\/0008-5472.CAN-05-0425","article-title":"Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0030","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"23","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.275.5300.665","article-title":"Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate","volume":"275","author":"Franke","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/excr.1999.4701","article-title":"Signaling by distinct classes of phosphoinositide 3-kinases","volume":"253","author":"Vanhaesebroeck","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/humu.9316","article-title":"PIK3CA mutations in advanced ovarian carcinomas","volume":"25","author":"Wang","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/5042","article-title":"PIK3CA is implicated as an oncogene in ovarian cancer","volume":"21","author":"Shayesteh","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0055","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0060","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/1078-0432.CCR-05-1024","article-title":"PIK3CA mutations in ovarian cancer","volume":"11","author":"Campbell","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00428-006-0358-3","article-title":"Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer","volume":"450","author":"Woenckhaus","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4161\/cbt.8.1.7209","article-title":"PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients","volume":"8","author":"Kolasa","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0075","first-page":"266","article-title":"Thioridazine in the management of cancer-related sweating","volume":"15","author":"Cowap","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(02)00018-7","article-title":"Fever and sweats in the patient with advanced cancer","volume":"16","author":"Zhukovsky","year":"2002","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1191\/0269216302pm570oa","article-title":"Depression in palliative care: a systematic review: Part 2. Treatment","volume":"16","author":"Ly","year":"2002","journal-title":"Palliat Med"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0090","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/bjc.1984.207","article-title":"Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells","volume":"50","author":"Ramu","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0095","first-page":"839","article-title":"Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine","volume":"76","author":"Akiyama","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF00217059","article-title":"Cytotoxic effects of neuroleptic drugs","volume":"91","author":"Munyon","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0105","first-page":"5399","article-title":"Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine","volume":"50","author":"Strobl","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-2999(96)00526-2","article-title":"Calmodulin antagonists decrease glucose 1, 6-bisphosphate, fructose 1, 6-bisphosphate, ATP and viability of melanoma cells","volume":"313","author":"Glass-Marmor","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/mutage\/14.2.243","article-title":"A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids","volume":"14","author":"Pantazaki","year":"1999","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0120","first-page":"3190","article-title":"Correlation between reversing of multidrug resistance and inhibiting of [3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line","volume":"49","author":"Kamiwatari","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.bjp.0704672","article-title":"Thioridazine interacts with the membrane of mitochondria acquiring antioxidant activity toward apoptosis\u2014potentially implicated mechanisms","volume":"136","author":"Rodrigues","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0130","first-page":"247","article-title":"Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action","volume":"57","author":"Basta-Kaim","year":"2006","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1385\/JMN:22:3:189","article-title":"Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors","volume":"22","author":"Gil-Ad","year":"2004","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0140","first-page":"107","article-title":"Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth","volume":"15","author":"Gil-Ad","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0145","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc2044","article-title":"The Connectivity Map: a new tool for biomedical research","volume":"7","author":"Lamb","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/81715","article-title":"Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha","volume":"26","author":"Fruman","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0165","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1158\/1078-0432.CCR-05-0206","article-title":"Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma","volume":"11","author":"Hu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0170","first-page":"880","article-title":"In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)","volume":"6","author":"Hu","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0175","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0180","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0185","first-page":"1982","article-title":"Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro","volume":"55","author":"Shi","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-007-0609-2","article-title":"Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines","volume":"62","author":"Aissat","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0195","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ejca.2005.12.018","article-title":"Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel","volume":"42","author":"Faried","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0200","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0205","doi-asserted-by":"crossref","first-page":"38879","DOI":"10.1074\/jbc.M505733200","article-title":"Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes","volume":"280","author":"Chen","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0210","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.4161\/cbt.8.13.8726","article-title":"Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells","volume":"8","author":"Rao","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0215","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00613621","article-title":"Serum concentration and protein binding of thioridazine and its metabolites in patients with chronic alcoholism","volume":"23","author":"Axelsson","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0225","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(88)90202-4","article-title":"Thioridazine: a radiation enhancer in advanced cervical cancer?","volume":"2","author":"Hercbergs","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2010.10.003_bb0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(72)92955-8","article-title":"Chlorpromazines and cancer","volume":"2","author":"Csatary","year":"1972","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810007481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810007481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T04:54:47Z","timestamp":1544158487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810007481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0090825810007481"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.10.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}